Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 71
Selected: 0
NCT IDTitle
NCT02413827A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
NCT04930783NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
NCT05029999CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT01460134A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT03358719DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT02200380A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
NCT06650761A Phase I Study of CDX-622
NCT01498328A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT02839265FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
NCT02014909A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
NCT02302339A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
NCT04364230Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
NCT02473731A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
NCT04944862A Study of CDX-0159 in Patients With Prurigo Nodularis
NCT05774184A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT05484011A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06727552A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT00458601Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
NCT06366750A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT02924038A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
NCT02642016A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
NCT02284971Pilot Study of SBRT and CDX-1127 in Prostate Cancer
NCT03580382Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
NCT03789097Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT04440943A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT07256392Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT03307746A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma
NCT04536077Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
NCT03804944Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
NCT01791686Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
NCT04146129A Phase 1 Study of CDX-0159
NCT02543645A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT04491084FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
NCT00412828A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
NCT04548869A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
NCT00104065Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
NCT01465139A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
NCT03254927A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT04538794A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT03329950A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT00709462A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT03688178DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
NCT02713828Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
NCT05031624A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
NCT01976585In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
NCT01480479Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT02335918A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
NCT02386111A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma